Integra LifeSciences Introduces Wound Matrix

Zacks Equity Research
March 28, 2014

New Jersey-based Integra LifeSciences Holding Corporation (IART) has expanded its skin and wound product line with the launch of Integra Wound Matrix (Thin). However, the announcement failed to boost Integra's shares as they fell 2.5% till the last trading session.

Wound Matrix is a new and thinner product with a thickness that is about half of the previous Integra Wound Matrix. It can be applied to complex anatomical sites that need a more conformable graft.

The product has received 510(k) clearance from the U.S. Food and Drug Administration (:FDA). The company expects to fully launch this product in the U.S. next month. It has been featured at the American Burn Association Annual Meeting from Mar 25 to 28, 2014 in Boston, Mass.

This new product is a collagen-glycosaminoglycan wound matrix, which supports a healing environment for wound management. It is available in a variety of sizes and can be used to treat second-degree burns, partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor site/grafts, post Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, skin tears) and draining wounds. The terminally sterilized Integra Wound Matrix (Thin) has a 24-month shelf life when stored at room temperature but for single use only

Integra LifeSciences, a leading surgical implants and medical instruments maker, offers a versatile range of skin repair solutions to meet the surgeon's procedural needs. Its skin products include Integra Dermal Regeneration Template, one of the first regenerative products approved by the FDA, Integra Meshed Milayer Wound Matrix, which can be used with Negative Pressure Wound Therapy, and Integra Flowable Wound Matrix, designed for easy treatment of tunneled and undermined wounds.

Integra LifeSciences, which currently carries a Zacks Rank #3 (Hold), offers orthopedic extremity surgery, neurosurgery, reconstructive, spine and general surgery. The company's Ultra Pure Collagen is the base material of implants and has been successfully used in more than 12 million procedures.

Some better-ranked stocks worth considering in the broader medical sector include ANI Pharmaceuticals, Inc. (ANIP), Alkermes plc (ALKS) and Alexion Pharmaceuticals, Inc. (ALXN), all of which hold a Zacks rank #1 (Strong Buy).

Read the Full Research Report on IART
Read the Full Research Report on ANIP
Read the Full Research Report on ALXN
Read the Full Research Report on ALKS

Zacks Investment Research